<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01509677</url>
  </required_header>
  <id_info>
    <org_study_id>RO-2455-402-RD</org_study_id>
    <secondary_id>2011-000582-13</secondary_id>
    <secondary_id>U1111-1155-8767</secondary_id>
    <secondary_id>D7120C00003</secondary_id>
    <nct_id>NCT01509677</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A 16-week, Randomized, Placebo-controlled, Double Blind, and Parallel Group Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the Biopsy trial is to investigate the effect of roflumilast 500 µg tablets
      once daily versus placebo on inflammation parameters in bronchial biopsy tissue specimen and
      additional in sputum and blood serum. Also data on safety status will be obtained.

      Patients to be included required to have moderate to severe COPD associated with chronic
      bronchitis. The total duration of this randomized, multicentre, phase III trial is 24 weeks
      maximum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a multicenter, double-blind, randomized, parallel group, phase 3 study. Patients
      included had a history of COPD (GOLD stage II-III, in Germany stage II only) with chronic
      productive cough.

      There were 2 parallel treatment arms (placebo and roflumilast 500 μg once daily). A 1 to 1
      randomization scheme was used, that is, patients were allocated to roflumilast 500 μg or
      placebo in equal proportions. Randomization was stratified by concomitant LABA use.

      The total duration of this study was 24 weeks maximum per patient. The study consisted of the
      following periods:

        -  Single-blind placebo run-in period (6 weeks) with visits at Week -6 (visit 0 [V0]), Week
           -2 (V1), and Week 0 (V2, randomization visit), during which all patients received
           placebo.

        -  Double-blind treatment period (16 weeks) during which patients received either
           roflumilast or matching placebo with visits at Week 6 (V4), Week 14 (V5), and Week 16
           (V6).

      An additional visit (V3) within 2 weeks after bronchoscopy/bronchial biopsy was performed
      purely as a safety visit. The exact timing of this safety visit was to be determined by the
      investigator. Safety follow-up. All AEs were followed up to 30 days after the double-blind
      treatment period. An additional safety visit, V7, was scheduled within 2 weeks after the
      second bronchoscopy. The exact timing of the safety visit was to be determined by the
      investigator.

      Patients were required not to take any food or drink overnight for at least 8 hours prior to
      returning to the study center for each visit. Patients were also asked to avoid strenuous
      exercise for 8 hours prior to each study visit and to avoid smoking for 4 hours prior to each
      study visit.

      For visits where patients did not undergo blood collections or biopsies, the fasting
      requirement was only mandated if clinically indicated, per investigator judgment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2012</start_date>
  <completion_date type="Actual">February 1, 2016</completion_date>
  <primary_completion_date type="Actual">February 1, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of CD8+ Inflammatory Cells in Bronchial Biopsy Tissue.</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Number of CD8+ Inflammatory Cells in Bronchial Biopsy Tissue</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD68+ Count in Biopsied Material (Submucosa)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD68+ Cell Count in Biopsied Material (Submucosa): Poisson Regression (Ratio)</measure>
    <time_frame>16 weeks</time_frame>
    <description>CD68+ Cell Count in Biopsied Material (submucosa): Poisson regression (ratio). Clarification: Measure type described as &quot;Number&quot; refers to &quot;Risk of each treatment group&quot;. It is not possible to select &quot;risk&quot; from this template so &quot;number&quot; was selected instead. This issue applies to similar variables reporting poisson regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From V2 to V6 in CD68+ Cell Count (Cells/mm^2) in Biopsied Material (Submucosa) (ITT)</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model</measure>
    <time_frame>16 weeks</time_frame>
    <description>CD4+ Cell Counts in biopsied Material (submucosa):poisson regression model. Clarification: Measure type &quot;Number&quot; refers to &quot;Risk of each treatment group&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD45+ Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model</measure>
    <time_frame>16 weeks</time_frame>
    <description>CD45+ Cell Counts in biopsied Material (submucosa):poisson regression model. Clarification: Measure type &quot;Number&quot; refers to &quot;treatment risk&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophils Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
    <description>Neutrophils Cell Counts in biopsied Material (submucosa):poisson regression model. Clarification: Measure type &quot;Number&quot; refers to &quot;Treatment risk&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8+ Cell Count in Biopsied Material (Bronchial Epithelium): Poisson Regression Model</measure>
    <time_frame>16 weeks</time_frame>
    <description>CD8+ Cell Count in biopsied material (Bronchial Epithelium): poisson regression model. Clarification: Measure Type &quot;Number&quot; refers to &quot;Treatment risk&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD68+ Cell Count in Biopsied Material (Bronchial Epithelium):Poisson Regression Model</measure>
    <time_frame>16 weeks</time_frame>
    <description>CD68+ Cell Count in biopsied material (Bronchial Epithelium):poisson regression model. Clarification: Measure type &quot;Number&quot; refers to &quot;Treatment Risk&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From V1 to V5 in Absolute Cell Count in Induced Sputum (10^6 Neutrophils/mL): Between-Treatment Difference</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Macrophages/mL): Between-Treatment Difference</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Eosinophils/mL): Between-Treatment Difference</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Lymphocytes/mL): Between-Treatment Difference</measure>
    <time_frame>BAseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Neutrophils/mL)</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Macrophages/mL)</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Eosinophils/mL)</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Lymphocytes)/mL)</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (Alfa- 2-Macroglobulin (µg/mL))</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (IL-8 (pg/mL))</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (MMP Type 9 (ng/mL))</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (MCP-1 (pg/mL))</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (TIMP-1 (ng/mL))</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (VEGF (pg/mL))</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (Alfa-2-Macroglobulin (µg/mL))</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (IL-8 (pg/mL))</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (MMP Type 9 (ng/mL))</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (MCP-1(pg/mL))</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (TIMP-1(ng/mL))</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (VEGF(pg/mL))</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lung Function Variables: Between-Treatment Differences (FAS) (FEV1 (L))</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lung Function Variables: Between-Treatment Differences (FAS) (FVC (L))</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wicoxon Signed-rank Test for Change From V2 to V6 in Post-bronchodilator FEV1/FVC</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
    <description>Wilcoxon test is a non-parametric test to evaluate differences among treatments in the variable that is being reported here. The data reported in the outcome measure data table are hodges Lehmann estimate of change from baseline in FEV1/FVC ratio.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>COPD</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Roflumilast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 μg tablet, once daily, oral administration in the morning after breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>tablet, once daily, oral administration in the morning after breakfast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>500 μg tablet, once daily, oral administration in the morning after breakfast</description>
    <arm_group_label>Roflumilast</arm_group_label>
    <other_name>Daxas</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet, once daily, oral administration in the morning after breakfast</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo to Roflumilast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          -  Giving written informed consent

          -  History of COPD (according to GOLD 2009) for at least 12 months prior to baseline
             visit V0 associated with chronic productive cough for at least three months in each of
             the two years prior to baseline visit V0 (with other causes of productive cough
             excluded)

          -  Outpatients 40-80 years of age

          -  Post-bronchodilator 30% ≤FEV1 ≤80% predicted

          -  Post-bronchodilator FEV1/FVC ratio ≤70%

          -  Current or former smokers with smoking history ≥20 pack years

        Main Exclusion Criteria:

        • Criteria affecting the read-out parameters of the trial:

          -  Clinical instability, defined as experiencing a COPD exacerbation six months prior to
             V0

          -  An upper/lower respiratory tract infection which has not resolved four weeks prior to
             V0

          -  Diagnosis of asthma and/or other relevant lung disease

          -  Known alpha-1-antitrypsin deficiency

          -  Suspicion or diagnosis of a bleeding disorders irrespective of its pathophysiological
             mechanism

          -  Other protocol-defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca AstraZeneca</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kobenhavn NV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>København NV</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grosshansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Immenhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dafen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4560&amp;filename=RO-2455-402-RD_ROBERT_Updated_Protocol_v6.0_(Amendment_12)_-_Redacted.pdf</url>
    <description>RO-2455-402-RD Updated Protocol v 6.0 (Amendment 12)</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 21, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2012</study_first_posted>
  <results_first_submitted>January 23, 2017</results_first_submitted>
  <results_first_submitted_qc>November 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 29, 2019</results_first_posted>
  <last_update_submitted>November 27, 2019</last_update_submitted>
  <last_update_submitted_qc>November 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Roflumilast</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>R500</title>
          <description>Roflumilast 500 µg</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo to Roflumilast</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>R500</title>
          <description>Roflumilast 500 µg</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo to Roflumilast</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="158"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="8.23"/>
                    <measurement group_id="B2" value="62.5" spread="8.43"/>
                    <measurement group_id="B3" value="63.2" spread="8.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of CD8+ Inflammatory Cells in Bronchial Biopsy Tissue.</title>
        <time_frame>16 weeks</time_frame>
        <population>The CD8+ cells count results in submucosa for the primary outcome were available for 117 patients at V2 (41 missing) and 114 patients at V6 (44 missing). The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See section 11.4.1 in CSR</population>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Number of CD8+ Inflammatory Cells in Bronchial Biopsy Tissue.</title>
          <population>The CD8+ cells count results in submucosa for the primary outcome were available for 117 patients at V2 (41 missing) and 114 patients at V6 (44 missing). The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See section 11.4.1 in CSR</population>
          <units>CD8+ cells count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="442.4" spread="312.74" lower_limit="0.82" upper_limit="1.30"/>
                    <measurement group_id="O2" value="427.1" spread="261.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Number of CD8+ Inflammatory Cells in Bronchial Biopsy Tissue</title>
        <time_frame>Baseline to 16 weeks</time_frame>
        <population>The CD8+ cells count results in submucosa for the primary outcome were available for 117 patients at V2 (41 missing) and 114 patients at V6 (44 missing). The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See section 11.4.1 in CSR</population>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of CD8+ Inflammatory Cells in Bronchial Biopsy Tissue</title>
          <population>The CD8+ cells count results in submucosa for the primary outcome were available for 117 patients at V2 (41 missing) and 114 patients at V6 (44 missing). The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See section 11.4.1 in CSR</population>
          <units>cells/mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="302.69"/>
                    <measurement group_id="O2" value="29.4" spread="298.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided test at 5% significant level</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.7922</p_value>
            <p_value_desc>This is p-value testing significance of &quot;treatment&quot; effect</p_value_desc>
            <method>Poisson regression model</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7917</p_value>
            <method>Poisson regression model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.120</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD68+ Count in Biopsied Material (Submucosa)</title>
        <time_frame>16 weeks</time_frame>
        <population>The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See 11.4.7 in CSR</population>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>CD68+ Count in Biopsied Material (Submucosa)</title>
          <population>The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See 11.4.7 in CSR</population>
          <units>CD68+ Count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.1" spread="113.91"/>
                    <measurement group_id="O2" value="124.4" spread="93.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided, 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.7145</p_value>
            <p_value_desc>This is p-value testing significance of &quot;treatment&quot; effect</p_value_desc>
            <method>Poisson regression model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD68+ Cell Count in Biopsied Material (Submucosa): Poisson Regression (Ratio)</title>
        <description>CD68+ Cell Count in Biopsied Material (submucosa): Poisson regression (ratio). Clarification: Measure type described as &quot;Number&quot; refers to &quot;Risk of each treatment group&quot;. It is not possible to select &quot;risk&quot; from this template so &quot;number&quot; was selected instead. This issue applies to similar variables reporting poisson regression.</description>
        <time_frame>16 weeks</time_frame>
        <population>The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See 11.4.7 in CSR</population>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>CD68+ Cell Count in Biopsied Material (Submucosa): Poisson Regression (Ratio)</title>
          <description>CD68+ Cell Count in Biopsied Material (submucosa): Poisson regression (ratio). Clarification: Measure type described as &quot;Number&quot; refers to &quot;Risk of each treatment group&quot;. It is not possible to select &quot;risk&quot; from this template so &quot;number&quot; was selected instead. This issue applies to similar variables reporting poisson regression.</description>
          <population>The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See 11.4.7 in CSR</population>
          <units>CD68+ Cell Count</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.8" spread="NA"/>
                    <measurement group_id="O2" value="121.6" spread="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.7136</p_value>
            <method>Poisson regression model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.119</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From V2 to V6 in CD68+ Cell Count (Cells/mm^2) in Biopsied Material (Submucosa) (ITT)</title>
        <time_frame>Baseline and 16 weeks</time_frame>
        <population>The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See 11.4.7 in CSR</population>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From V2 to V6 in CD68+ Cell Count (Cells/mm^2) in Biopsied Material (Submucosa) (ITT)</title>
          <population>The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See 11.4.7 in CSR</population>
          <units>CD68+ Cell Count (cells/mm^2)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="10.99"/>
                    <measurement group_id="O2" value="-5.3" spread="11.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.4606</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>15.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-19.2</ci_lower_limit>
            <ci_upper_limit>42.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+ Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model</title>
        <description>CD4+ Cell Counts in biopsied Material (submucosa):poisson regression model. Clarification: Measure type &quot;Number&quot; refers to &quot;Risk of each treatment group&quot;.</description>
        <time_frame>16 weeks</time_frame>
        <population>The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See 11.4.7 in CSR</population>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model</title>
          <description>CD4+ Cell Counts in biopsied Material (submucosa):poisson regression model. Clarification: Measure type &quot;Number&quot; refers to &quot;Risk of each treatment group&quot;.</description>
          <population>The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See 11.4.7 in CSR</population>
          <units>CD4+ Cell Counts</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304.6" spread="NA"/>
                    <measurement group_id="O2" value="255.0" spread="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.2744</p_value>
            <method>Poisson regression model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.194</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD45+ Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model</title>
        <description>CD45+ Cell Counts in biopsied Material (submucosa):poisson regression model. Clarification: Measure type &quot;Number&quot; refers to &quot;treatment risk&quot;</description>
        <time_frame>16 weeks</time_frame>
        <population>The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See 11.4.7 in CSR</population>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>CD45+ Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model</title>
          <description>CD45+ Cell Counts in biopsied Material (submucosa):poisson regression model. Clarification: Measure type &quot;Number&quot; refers to &quot;treatment risk&quot;</description>
          <population>The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See 11.4.7 in CSR</population>
          <units>CD45+ Cell Counts</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="818.4" spread="NA"/>
                    <measurement group_id="O2" value="960.3" spread="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.1128</p_value>
            <method>Poisson regression model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.086</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutrophils Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model</title>
        <description>Neutrophils Cell Counts in biopsied Material (submucosa):poisson regression model. Clarification: Measure type &quot;Number&quot; refers to &quot;Treatment risk&quot;</description>
        <time_frame>Baseline to 14 weeks</time_frame>
        <population>The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See 11.4.7 in CSR</population>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Neutrophils Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model</title>
          <description>Neutrophils Cell Counts in biopsied Material (submucosa):poisson regression model. Clarification: Measure type &quot;Number&quot; refers to &quot;Treatment risk&quot;</description>
          <population>The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See 11.4.7 in CSR</population>
          <units>Neutrophils Cell Counts</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.6" spread="NA"/>
                    <measurement group_id="O2" value="127.7" spread="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.6740</p_value>
            <method>Regression, Linear</method>
            <method_desc>Poisson regression model</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.164</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD8+ Cell Count in Biopsied Material (Bronchial Epithelium): Poisson Regression Model</title>
        <description>CD8+ Cell Count in biopsied material (Bronchial Epithelium): poisson regression model. Clarification: Measure Type &quot;Number&quot; refers to &quot;Treatment risk&quot;</description>
        <time_frame>16 weeks</time_frame>
        <population>The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See 11.4.7 in CSR</population>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>CD8+ Cell Count in Biopsied Material (Bronchial Epithelium): Poisson Regression Model</title>
          <description>CD8+ Cell Count in biopsied material (Bronchial Epithelium): poisson regression model. Clarification: Measure Type &quot;Number&quot; refers to &quot;Treatment risk&quot;</description>
          <population>The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See 11.4.7 in CSR</population>
          <units>CD8+ Cell Count</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="422.1" spread="NA"/>
                    <measurement group_id="O2" value="505.3" spread="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0677</p_value>
            <method>Poisson regression model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.082</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD68+ Cell Count in Biopsied Material (Bronchial Epithelium):Poisson Regression Model</title>
        <description>CD68+ Cell Count in biopsied material (Bronchial Epithelium):poisson regression model. Clarification: Measure type &quot;Number&quot; refers to &quot;Treatment Risk&quot;</description>
        <time_frame>16 weeks</time_frame>
        <population>The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See 11.4.7 in CSR</population>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>CD68+ Cell Count in Biopsied Material (Bronchial Epithelium):Poisson Regression Model</title>
          <description>CD68+ Cell Count in biopsied material (Bronchial Epithelium):poisson regression model. Clarification: Measure type &quot;Number&quot; refers to &quot;Treatment Risk&quot;</description>
          <population>The reason for missing samples was that the sample amount did not reach the minimal area requested per study protocol. See 11.4.7 in CSR</population>
          <units>CD68+ Cell Count</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.3" spread="NA"/>
                    <measurement group_id="O2" value="93.1" spread="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.3566</p_value>
            <method>Poisson regression model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.177</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From V1 to V5 in Absolute Cell Count in Induced Sputum (10^6 Neutrophils/mL): Between-Treatment Difference</title>
        <time_frame>Baseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From V1 to V5 in Absolute Cell Count in Induced Sputum (10^6 Neutrophils/mL): Between-Treatment Difference</title>
          <units>10^6 neutrophils/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7181" spread="1.64471"/>
                    <measurement group_id="O2" value="0.0827" spread="1.61220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2 sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.4794</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.6354</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.30185</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9429</ci_lower_limit>
            <ci_upper_limit>6.2137</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Macrophages/mL): Between-Treatment Difference</title>
        <time_frame>Baseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Macrophages/mL): Between-Treatment Difference</title>
          <units>10^6 macrophages/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1017" spread="0.23396"/>
                    <measurement group_id="O2" value="-0.3710" spread="0.22970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2 sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.1541</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.4727</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.32866</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1810</ci_lower_limit>
            <ci_upper_limit>1.1264</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Eosinophils/mL): Between-Treatment Difference</title>
        <time_frame>Baseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Eosinophils/mL): Between-Treatment Difference</title>
          <units>10^6 eosinophils/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0986" spread="0.02639"/>
                    <measurement group_id="O2" value="-0.0360" spread="0.02585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2 sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0927</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0626</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03681</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1358</ci_lower_limit>
            <ci_upper_limit>0.0106</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Lymphocytes/mL): Between-Treatment Difference</title>
        <time_frame>BAseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Lymphocytes/mL): Between-Treatment Difference</title>
          <units>10^6 lymphocytes/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0167" spread="0.01167"/>
                    <measurement group_id="O2" value="-0.0060" spread="0.01141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2 sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.5175</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0107</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01647</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0435</ci_lower_limit>
            <ci_upper_limit>0.0220</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Neutrophils/mL)</title>
        <time_frame>Baseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Neutrophils/mL)</title>
          <units>10^6 neutrophils/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.527" spread="2.3571"/>
                    <measurement group_id="O2" value="0.382" spread="2.3535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5 % test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.5205</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.146</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.3253</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.466</ci_lower_limit>
            <ci_upper_limit>8.757</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Macrophages/mL)</title>
        <time_frame>Baseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Macrophages/mL)</title>
          <units>10^6 macrophages/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.315" spread="2.1328"/>
                    <measurement group_id="O2" value="-0.826" spread="2.1316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5 % test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.7052</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.141</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.0057</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.835</ci_lower_limit>
            <ci_upper_limit>7.117</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Eosinophils/mL)</title>
        <time_frame>Baseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Eosinophils/mL)</title>
          <units>10^6 eosinophils/m</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.826" spread="0.5214"/>
                    <measurement group_id="O2" value="-0.041" spread="0.5200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5 % test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0127</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.867</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7331</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.324</ci_lower_limit>
            <ci_upper_limit>-0.409</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Lymphocytes)/mL)</title>
        <time_frame>Baseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Lymphocytes)/mL)</title>
          <units>10^6 lymphocytes)/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.137" spread="0.1332"/>
                    <measurement group_id="O2" value="-0.086" spread="1.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5 % test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.7862</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.051</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1871</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.423</ci_lower_limit>
            <ci_upper_limit>0.321</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (Alfa- 2-Macroglobulin (µg/mL))</title>
        <time_frame>Baseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (Alfa- 2-Macroglobulin (µg/mL))</title>
          <units>µg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.730"/>
                    <measurement group_id="O2" value="-0.48" spread="0.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.8769</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.005</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.84</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (IL-8 (pg/mL))</title>
        <time_frame>Baseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (IL-8 (pg/mL))</title>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-827.3" spread="1995.79"/>
                    <measurement group_id="O2" value="-1538.4" spread="1941.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.7978</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>711.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2768.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4778.3</ci_lower_limit>
            <ci_upper_limit>6200.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (MMP Type 9 (ng/mL))</title>
        <time_frame>Baseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (MMP Type 9 (ng/mL))</title>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.1" spread="57.07"/>
                    <measurement group_id="O2" value="-8.4" spread="55.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.2669</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>88.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>79.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.6</ci_lower_limit>
            <ci_upper_limit>245.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (MCP-1 (pg/mL))</title>
        <time_frame>Baseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (MCP-1 (pg/mL))</title>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-95.2" spread="49.23"/>
                    <measurement group_id="O2" value="-69.3" spread="46.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.7033</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-25.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>67.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-160.3</ci_lower_limit>
            <ci_upper_limit>108.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (TIMP-1 (ng/mL))</title>
        <time_frame>Baseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (TIMP-1 (ng/mL))</title>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.87" spread="13.085"/>
                    <measurement group_id="O2" value="-1.92" spread="12.551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.1264</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>27.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>18.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.97</ci_lower_limit>
            <ci_upper_limit>63.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (VEGF (pg/mL))</title>
        <time_frame>Baseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (VEGF (pg/mL))</title>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.1" spread="89.46"/>
                    <measurement group_id="O2" value="-43.7" spread="86.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0185</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>296.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>124.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>50.9</ci_lower_limit>
            <ci_upper_limit>542.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (Alfa-2-Macroglobulin (µg/mL))</title>
        <time_frame>Baseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (Alfa-2-Macroglobulin (µg/mL))</title>
          <units>µg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.061"/>
                    <measurement group_id="O2" value="-0.05" spread="0.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.9989</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.086</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (IL-8 (pg/mL))</title>
        <time_frame>Baseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (IL-8 (pg/mL))</title>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.48" spread="0.929"/>
                    <measurement group_id="O2" value="-3.92" spread="0.945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.6701</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.309</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.15</ci_lower_limit>
            <ci_upper_limit>2.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (MMP Type 9 (ng/mL))</title>
        <time_frame>Baseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (MMP Type 9 (ng/mL))</title>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.78"/>
                    <measurement group_id="O2" value="-1.0" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.1105</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (MCP-1(pg/mL))</title>
        <time_frame>Baseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (MCP-1(pg/mL))</title>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.8" spread="11.0"/>
                    <measurement group_id="O2" value="-23.4" spread="11.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.9261</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>15.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.4</ci_lower_limit>
            <ci_upper_limit>29.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (TIMP-1(ng/mL))</title>
        <time_frame>Baseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (TIMP-1(ng/mL))</title>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="3.19"/>
                    <measurement group_id="O2" value="-7.5" spread="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0257</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>19.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (VEGF(pg/mL))</title>
        <time_frame>Baseline to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (VEGF(pg/mL))</title>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="12.80"/>
                    <measurement group_id="O2" value="-21.5" spread="13.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0728</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>32.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>18.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>168.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lung Function Variables: Between-Treatment Differences (FAS) (FEV1 (L))</title>
        <time_frame>Baseline to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lung Function Variables: Between-Treatment Differences (FAS) (FEV1 (L))</title>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.028" spread="0.0212"/>
                    <measurement group_id="O2" value="-0.035" spread="0.0212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0380</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.063</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0300</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.004</ci_lower_limit>
            <ci_upper_limit>0.122</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lung Function Variables: Between-Treatment Differences (FAS) (FVC (L))</title>
        <time_frame>Baseline to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lung Function Variables: Between-Treatment Differences (FAS) (FVC (L))</title>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.031" spread="0.0391"/>
                    <measurement group_id="O2" value="-0.033" spread="0.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2-sided 5% test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.2482</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.064</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0552</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.045</ci_lower_limit>
            <ci_upper_limit>0.173</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wicoxon Signed-rank Test for Change From V2 to V6 in Post-bronchodilator FEV1/FVC</title>
        <description>Wilcoxon test is a non-parametric test to evaluate differences among treatments in the variable that is being reported here. The data reported in the outcome measure data table are hodges Lehmann estimate of change from baseline in FEV1/FVC ratio.</description>
        <time_frame>Baseline to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R500</title>
            <description>Roflumilast 500 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Roflumilast</description>
          </group>
        </group_list>
        <measure>
          <title>Wicoxon Signed-rank Test for Change From V2 to V6 in Post-bronchodilator FEV1/FVC</title>
          <description>Wilcoxon test is a non-parametric test to evaluate differences among treatments in the variable that is being reported here. The data reported in the outcome measure data table are hodges Lehmann estimate of change from baseline in FEV1/FVC ratio.</description>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-1" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2 sided 5 % test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.2629</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Between treatment difference</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.00</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>R500</title>
          <description>Roflumilast 500 µg</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo to Roflumilast</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Influenza A virus test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Spermatocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.02</frequency_threshold>
        <default_vocab>MedDRA version18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Forced expiratory volume decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Haedache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>AstraZeneca Clinical Study Information Center</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

